Bhagirath Dholaria, MD
@DholariaMD
ID:1045484432369569792
28-09-2018 01:24:47
194 Tweets
280 Followers
102 Following
📢Join us TODAY!
IACH for Patients:
CAR T cell therapy for relapsed lymphoma: Journey from being a patient to a survivor
⏲️7PM CET
Register for FREE⏬
bit.ly/4adEkYI
Mohamad Mohty Bhagirath Dholaria, MD
🌟NEW initiative by IACH
IACH for Patients⬇️
youtube.com/watch?v=8Sjyij…
📣Join the first webinar:
CAR T cell therapy for relapsed lymphoma: Journey from being a patient to a survivor
🗓️March 25
⏲️7PM CET
Register for FREE⏬
bit.ly/4adEkYI
Mohamad Mohty Bhagirath Dholaria, MD
Mentor of many, friend of everyone. Congratulations Bipin Savani
Vanderbilt-Ingram Cancer Center @ASTC Mohamad Mohty IACH
📢Join us for the upcoming IACH Junior Club:
A Challenging Odyssey through AML: Confronting aGvHD, TMA, PRES after alloHCT
🗓️Feb 8 2024
⏲️6PM CET, 12PM NY
Register for FREE
⬇️⬇️
bit.ly/4bnmC6o
Florent Malard Bhagirath Dholaria, MD Esra Gülderen Mohamad Mohty
📢Join us for the upcoming post #ASH23 Transplant/CT roundtable by IACH
🗓️Jan 16 2024
⏲️7PM CET, 1PM NY
Register for FREE🔽
bit.ly/47v5gl0
Mohamad Mohty Florent Malard A Samer Al-Homsi Bhagirath Dholaria, MD Leo Luznik Arnon Nagler
LIVE NOW! Survivorship and GVHD management in ALLO SCT Recipients from our veteran SCT NP. IACH GvHD Hub Vanderbilt-Ingram Cancer Center Bipin Savani
.President Biden on Friday named Kimryn Rathmell to be the next director of the National Cancer Institute.
Rathmell will become the NCI’s 17th director and only the second woman to hold this position leading the nation’s fight against cancer.
Congratulations, Dr. Rathmell!
spr.ly/6013u0WCt
What 3 leukemia/SCT MDs discuss when they meet for early AM match. #CHIP #Biobank , #IndiaVsNewZealand ICC Cricket World Cup Ashwin Kishtagari, MD @somdebbal Bipin Savani
📢Join us this TODAY:
Inpatient Management of Acute Leukemia Undergoing High-Dose Chemotherapy
with Whitney Chase
Register for FREE🔽
bit.ly/3FF6bUD
Bhagirath Dholaria, MD Mohamad Mohty
Out in today Nature Medicine, nature.com/articles/s4159… FIH phase 1 trial with Elranatamab in R/R multiple myeloma defining the RP2D. High (ORR 64%) including in patients with high risk cytogenetics and prior anti-BCMA exposure. Responses were durable (DOR 17.1 mod, PFS 11.8 mod).
Please join our #Youngadult #cancer program #social event tomorrow 9/19/2023 at #nashville Von Elrod's for #HarryPotter #trivia night.Bhagirath Dholaria, MD Elizabeth Davis
Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center Vanderbilt Hem / Onc #Earlyonset Dr. jordan berlin Ben Ho Park
Excellent FREE opportunity to learn and connect with Myeloma team Vanderbilt-Ingram Cancer Center Insights @ VUMC. thank you The Leukemia & Lymphoma Society Bipin Savani Adetola Kassim International Myeloma Foundation
📣Join us this TUESDAY:
Logistics and patient monitoring of outpatient CAR T program
Free registration!⬇️
bit.ly/3rrfkMr
Bhagirath Dholaria, MD Brittney Baer Mohamad Mohty
Still looking for #myeloma weekend read? Very glad results from #UKMRA cooperative OPTIMUM MUKnine trial are out in Journal of Clinical Oncology – designed with Myeloma UK and patients to generate evidence for #access discussions for those with highest unmet need.
ascopubs.org/doi/10.1200/JC…